deltatrials
Completed PHASE4 INTERVENTIONAL NCT00110682

Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses

A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up

Sponsor: 3M

Conditions Actinic Keratosis Keratosis
Interventions Imiquimod used as an adjunct to cryotherapy
Updated 5 times since 2017 Last updated: Apr 21, 2008 Started: Apr 30, 2005 Primary completion: Oct 31, 2006 Completion: Dec 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Actinic Keratosis and Keratosis and is currently completed. 3M leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • 3M
  • Derm Research @ 888 Inc.
Data source: Derm Research @ 888 Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations